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ABSTRACT 
Aims: To investigate the clinical relevance of contemporary cutoffs of left ventricular ejection 
fraction (LVEF) including an intermediate phenotype with mid-range reduced ejection fraction 
(EF) among patients with coronary artery disease (CAD) undergoing percutaneous coronary 
intervention (PCI).  
Methods and Results: Patient-level data were summarized from five randomized clinical trials 
in which 6,198 patients underwent clinically indicated PCI in different clinical settings. We 
assessed all-cause mortality as primary endpoint at 5-year follow-up. According to the proposed 
LVEF cutoffs, 3,816 patients were included in the preserved LVEF group (LVEF≥50%), 1,793 in 
the mid-range reduced LVEF group (LVEF 40-49%), and 589 patients in the reduced LVEF 
group (LVEF<40%). Patients in the reduced LVEF group were at increased risk for the primary 
outcome of all-cause mortality compared with both, preserved and mid-range LVEF throughout 5 
years of follow-up (adjusted HR 2.39 (95%CI 1.75-3.28, p<0.001) and 1.68 (95%CI 1.34-2.10, 
p<0.001), respectively). The risk of cardiac death and the composite endpoint of cardiac death, 
myocardial infarction, or stroke were higher for patients in the reduced LVEF group compared 
with the preserved and mid-range reduced LVEF groups, but also for the mid-range LVEF 
compared to preserved LVEF group (adjusted p<0.05 for all comparisons) throughout 5 years.  
Irrespective of clinical presentation at baseline (stable CAD or acute coronary syndrome), 
patients with reduced or mid-range LVEF were at increased risk of all-cause mortality and 
cardiac death up to 5-years compared to the other group (adjusted p<0.05 for all comparisons). 
Conclusion: Patients with reduced LVEF<40% or mid-range LVEF 40-49% in the context of 
CAD undergoing clinically indicated PCI are at increased risk of all-cause mortality, cardiac 
death and the composite of cardiac death, stroke and myocardial infarction throughout 5 years 
of follow-up. The recently proposed LVEF cut-offs contribute to the differentiation and risk 
stratification of patients with ischemic heart disease. 
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INTRODUCTION 
Left ventricular dysfunction due to coronary artery disease (CAD) remains a major cause of 
morbidity and mortality with considerable burden of disease worldwide.1 Patients with left 
ventricular dysfunction and symptoms of heart failure (HF) represent a clinical challenge 
because of the complex pathophysiological substrate and comorbidity interplay.2 Previous 
studies of patients with CAD and reduced left ventricular ejection fraction (LVEF) (LVEF<40%) 
have shown favourable results of coronary revascularization (either with percutaneous coronary 
intervention (PCI) or coronary artery bypass grafting (CABG)) compared with a medical 
management alone.3, 4 However, the most recent guidelines of the American College of 
Cardiology Foundation (ACCF)/AHA and European Society of Cardiology are not uniform with 
respect to the class and level of treatment recommendations for patients with HF and CAD 
suitable for revascularization. The European Society of Cardiology (ESC) guidelines recommend 
any intervention that would achieve complete revascularization (CABG or PCI) for patients with 
HF and significant CAD in the presence of symptoms of angina and the presence of viable 
myocardium.5 The American College of Cardiology Foundation (ACCF)/AHA guidelines 
recommend CABG or PCI in patients with left main or multivessel disease in case of 
symptomatic patients without requiring evidence of ischemia.6 Recently, the ESC guidelines on 
acute and chronic HF suggested an additional intermediate phenotype in addition to the existing 
reduced LVEF of <40% and preserved LVEF of ≥50% referred to as heart failure with mid-range 
ejection fraction (LVEF 40-49%).7 Nevertheless, the chosen cutoff of 40% has been disputed as 
its prognostic relevance is under question and trials on neurohormonal antagonism have used 
different inclusion criteria.8  
Against this background, we sought to investigate the impact of left ventricular systolic function 
by applying the recently proposed LVEF cutoffs7 in a large sample of patients with CAD 
undergoing PCI in the context of different clinical settings. 
  
METHODS 
Data sources, study population and interventions 
We summarized patient-level data from five randomized clinical trials (SIRTAX (NCT00297661)9, 
LEADERS (NCT00389220)10, 11, RESOLUTE (NCT00617084)12, 13, COMFORTABLE 
(NCT00962416)14 and BIOSCIENCE (NCT01443104)15, 16) with long-term follow-up conducted 
from 2004 to 2014 at European institutions. Detailed individual study design and trial results are 
available in the individual publications of the trials (Supplementary Table 1).9-16 Briefly, all 
studies included patients with CAD referred for clinically indicated PCI in different clinical setting 
(corresponding to stable CAD, non-ST-elevation acute coronary syndrome (NSTE-ACS), or ST-
elevation myocardial infarction (STEMI)) that were amendable to coronary stent implantation. In 
the individual trials, patients were randomly assigned to one of two different stent platforms 
(either bare-metal (BMS) or drug-eluting stents (DES)) following pre-specified protocols 
(Supplementary Table 1).  For the purpose of this study, we included all patients with available 
information on left ventricular (LV) function. LV function was determined at baseline prior to the 
index intervention by left ventricular angiography or transthoracic echocardiography as reported 
in the case record form. 
All studies complied with the Declaration of Helsinki and were approved by the ethical 
review board in each institution. All patients in the individual trials had provided written informed 
consent to be prospectively followed. The case report forms were veriﬁed or checked for 
plausibility by an independent monitoring provider in the individual studies. The databases used 
in this study only contained anonymous patient records. 
 
Outcomes definitions and follow-up 
Assessed outcomes across the trials were adjudicated with similar standardized definitions as 
has been previously reported.17 The primary outcome in our analysis was all-cause mortality. 
Secondary outcomes included cardiac death, myocardial infarction (MI), composite of cardiac 
death, MI or stroke, Q-wave MI, non Q-Wave MI, stroke, any target lesion revascularization 
(TLR), any target-vessel revascularization (TVR), and any revascularization up to 5-years follow-
up. Follow-up in individual trials was prospectively performed at 30-days, 1-year and annually 
thereafter throughout 5-years. For this analysis, 5-year follow-up data were available for all trials. 
Individual patients were censored at the valid contact in case of lost-to-follow-up or withdrawal of 
the consent. 
 
Statistical analysis 
We stratified the study population according to the recently proposed LVEF cutoffs7 into three 
groups of ≥50%, 40-49%, and <40%. Descriptive statistics of baseline continuous variables were 
presented as mean ± standard deviation (SD) and compared with independent samples Student 
t-test; categorical variables were expressed as frequencies and percentages and compared with 
Fisher’s exact or chi-squared test. We evaluated different cut-offs in our dataset comparing them 
with the Harrel’s C index. Clinical outcomes at 5 years were expressed as counts with 
percentage for the overall population, and stratified according to clinical presentation (stable 
CAD or ACS). We performed additional analyses by breaking down the ACS group into two 
subgroups (NSTE-ACS and STEMI). We performed a survival parametric model with Weibull 
distribution, PH model, for the overall population and the stratified population to calculate hazard 
ratios (HRs) with accompanied 95% confidence intervals (CIs). We considered the different trials 
as random effect and we derived adjusted HRs performing maximum likelihood estimation from 
multivariable survival parametric models for the overall population and stratified groups for all the 
endpoints. We obtained adjusted HRs by considering baseline characteristics, excluding PCI 
related information and those variables with ≥30% of missing values or those variables not 
available in a particular study. Adjustment was performed for age, gender, body-mass index, 
diabetes mellitus, insulin-treatment, diabetes diet or oral treatment at baseline, hypertension, 
current smoker, family history of coronary artery disease, previous myocardial infarction, 
previous percutaneous coronary interventions, previous coronary artery bypass-graft, acute 
coronary syndrome group, renal failure, and glycoprotein IIb/IIIa antagonist use at procedure. 
We imputed the missing values by using multiple imputation to obtain the final model. The 
Kaplan-Meier curves, were obtained for the endpoints of all-cause mortality, cardiac death and 
the composite of cardiac death, MI and stroke; and stratified according to the specified LVEF 
groups. We considered a landmark analysis using a time point at 30-days, with HRs computed 
separately for events up to 30-days and from 30-days to 5-years. Finally, we used fractional 
polynomial to analyze the LVEF versus all-cause mortality. In the latter case, fractional 
polynomials with one degree were used to obtain the estimation of the effect of LVEF versus log 
hazard of all-cause mortality and the values were centered at the value of 50. HRs are 
considered statistically significant at 5% level. All statistical analyses were performed with Stata 
version 15.0 (StataCorp. 2017, College Station, TX). 
 
  
RESULTS 
Study population and baseline clinical characteristics 
A total of 8,287 patients were enrolled into 5 trials of whom 6,198 patients fulfilled the eligibility 
criteria and were included in this pooled analysis (Figure 1, Table 1). The Harrel’s C comparison 
in the study population confirms that for an unadjusted model the best cut-offs of LVEF for the 
mid-range reduced LVEF group are those proposed by the recent ESC guidelines (LVEF 40-
49%), while for the adjusted model, the best lower cut-off value would be a LVEF of 35% 
(Supplementary Table 2). According to the proposed LVEF cutoffs7, 3,816 patients were 
included in the preserved LVEF (≥50%) group, 1,793 mid-range reduced LVEF (40-49%) group, 
and 589 in the reduced LVEF (<40%) group. Table 1 and Supplementary Tables 3 and 4 
summarize baseline demographics and procedural characteristic of the study population. 
Baseline characteristics differed considerably across the three groups with patients in 
LVEF<40% group featuring a more severe cardiovascular-risk profile and a higher proportion of 
advanced Killip Class (III or IV) at presentation (Table 1).  In our study sample, 60% of patients 
presented with acute coronary syndromes (ACS) (29% NSTE-ACS and 31% STEMI). 
Multivessel revascularization was performed in 30% of the overall population and was equally 
represented across the three groups of LVEF.  
Clinical outcomes 
Clinical outcomes throughout 5 years are summarized in Supplementary Table 4 for the overall 
study population stratified according to LVEF group and clinical presentation. In crude analyses, 
patients with reduced LVEF<40% experienced higher rates of all-cause mortality compared with 
both, the preserved and mid-range reduced LVEF group (24% versus 8% and 13%, 
respectively) with unadjusted hazard ratios of 1.56 (95%CI, 1.36 to 1.80) for mid-range vs. 
preserved LVEF group, 3.32 (95%CI, 2.81 to 3.93) for reduced vs. preserved LVEF group, and 
2.13 (95%CI, 1.78 to 2.54) for reduced vs. mid-range reduced LVEF group (Supplementary 
Table 5) at 5 years of follow-up. Following multivariable adjustment, patients in the reduced 
LVEF<40% group remained at increased risk for all-cause mortality compared with preserved 
LVEF≥50% (adjusted HR 2.39 (95%CI 1.75 to 3.28), p<0.001) or mid-range LVEF 40-49% 
(adjusted HR 1.68 (95%CI 1.34 to 2.10), p<0.001) throughout 5 years of follow-up (Table 2 and 
Figure 2). The risk of cardiac death and the composite endpoint of cardiac death, myocardial 
infarction, or stroke remained higher for patients in the reduced LVEF group compared with 
either the preserved or mid-range LVEF group (adjusted p<0.05 for all comparisons). In a 
landmark analysis at 30 days of follow-up, the risk of all-cause mortality was higher for the 
reduced LVEF group compared with the preserved LVEF group (adjusted HR of 8.82 (95%CI, 
2.02 to 38.60), p<0.001).  The mid-range LVEF group remained at increased risk of all-cause 
mortality and cardiac death compared to the preserved LVEF group during the first 30 days and 
continued to be at increased risk up to 5 years (adjusted p<0.05 for all comparisons) (Table 2 
and Figure 2). The trend of risk over time for cardiac death was consistent with that for all-cause 
mortality with a higher risk for the reduced LVEF group compared with either the preserved 
LVEF (adjusted HR 3.07 (95%CI, 2.14 to 4.42), p<0.001) or the mid-range LVEF group 
(adjusted HR 1.74 (95%CI, 1.22 to 2.50), p=0.002) throughout  five years of follow-up.   
 
Outcomes according to initial clinical setting 
The clinical indication for PCI at baseline was ACS in 60% of the participants (either NSTE-ACS 
(29%) or STEMI (31%)), while 40% of the participants presented with stable CAD (Table 1). 
Detailed outcomes stratified according to initial clinical presentation and LVEF group at baseline 
are provided in Supplementary Table 4. The unadjusted analyses indicated an increased risk of 
all-cause mortality, cardiac death and the composite endpoint of cardiac death, MI, or stroke 
(p<0.05 for all comparisons of subgroups) across the entire spectrum of clinical presentations for 
reduced over preserved and mid-range LVEF group, and also for mid-range over preserved 
LVEF group (Supplementary Table 6 and 7). After adjusting for differences in baseline 
characteristics, patients with reduced LVEF (<40%) presenting with either stable CAD or ACS 
remained at increased risk of all-cause mortality and cardiac death compared to both preserved 
and mid-range LVEF group throughout 5 years of follow-up (p<0.05 for all comparisons) (Table 
3, Figure 3). Patients initially presenting with either stable CAD or ACS and reduced LVEF<40% 
were at increased risk of cardiac death compared with preserved LVEF≥50% (adjusted HR of 
2.64 (95%CI 1.71 to 4.06, p<0.001) and 3.48 (95%CI 2.27 to 5.33, p<0.001) respectively) 
(Supplementary Table 8 and Supplementary Figure). Patients with mid-range LVEF 40-49% 
were well differentiated and at higher risk of all-cause mortality and cardiac death compared to 
preserved LVEF≥50% in both clinical settings (adjusted p<0.001 for all comparisons) (Table 3).    
In a spline analysis using fractional polynomial stratified according to clinical setting at baseline 
(Figure 4) patients with lower LVEF had a higher hazard of all-cause mortality, particularly in the 
group of ACS patients. 
 
  
DISCUSSION 
The present study provides comprehensive evidence applying the recently proposed LVEF 
cutoffs to a large group of patients with CAD undergoing clinically indicated PCI followed 
throughout 5 years of follow-up with adjudicated clinical endpoint assessment in the context of 
carefully conducted randomized clinical trials. The salient findings of our analysis can be 
summarized as follows:  
- Patients with reduced LVEF<40% are at increased risk of all-cause mortality and cardiac 
death compared with those with preserved and mid-range LVEF throughout 5 years. 
- The difference in mortality emerges early (within 30 days) and continues to increase over 
time (throughout 5 years).  
- Patients with mid-range LVEF 40-49% are well differentiated and at increased risk of all-
cause mortality and cardiac death compared with those with preserved LVEF≥50% 
throughout 5 years. 
- The risk of all-cause mortality and cardiac death is higher for patients with reduced 
LVEF<40% irrespective of clinical indication (stable CAD or ACS) compared to preserved 
and mid-range reduced LVEF.  
 
The prognostic relevance of LVEF to appropriately risk stratify patients over the whole 
spectrum of LV function and heart failure phenotype remains subject of debate. In a post-hoc 
analysis of the CHARM trial, LVEF was shown to function as a good predictor of cardiovascular 
outcomes only for patients with heart failure and LVEF<45%.18 The ﬁndings of the Meta-analysis 
Global Group in Chronic Heart Failure (MAGGIC) indicated no signiﬁcant increase in the risk of 
all-cause mortality or cardiovascular death in patients with either LVEF 50–59% or 40-49% 
compared with patients with LVEF of 60% or above, whereas the hazard for death increased 
steadily below a LVEF of 40%.19 However, in our study sample, the proposed LVEF cut-offs did 
appropriately risk discriminate the patients among the spectrum of mid-range and preserved LV 
function. These findings are in concordance with recently published large scale meta-analysis, 
highlighting the distinct prognostic role of mid-range LVEF group.20, 21 
We were able to demonstrate that patients with impaired LVEF at baseline irrespective of 
initial clinical presentation (stable CAD or ACS) remain at increased risk of death compared to 
patients with either preserved or mid-range impaired LV function throughout 5 years. Most 
studies, of heart failure with depressed systolic function, report only a single LVEF 
measurement, generally obtained at baseline. Notwithstanding, the heart failure syndrome 
includes multiple diverging patient-specific phenotypes, resulting in a wide spectrum of LVEF 
trajectories over time depending on underlying aetiology, duration, and gender.22, 23 In a large 
prospective cohort of patients with heart failure and echocardiographic assessment of LV 
function at several time points (mean 3.6±1.7) over 15 years, LV function in patients with 
ischemic heart failure improved to a lesser degree compared with patients with non-ischemic 
heart failure within the first year of initial assessment followed by a relative plateau thereafter. Of 
note a decline in LVEF as compared to the preceding period was associated with higher 
mortality.22  The findings of our study corroborate those of  the HORIZONS-AMI trial, where 
severe LV dysfunction (LVEF<40%) determined during the acute phase of STEMI patients 
undergoing primary PCI was a powerful independent predictor of adverse clinical outcomes 
during 3 years follow-up.24 Similarly, a retrospective analysis of the CADILLAC trial reported an 
increased risk of all-cause mortality at 1 year of follow-up among STEMI patients with baseline 
LVEF<40% as compared to those with baseline LVEF>40%.25 The present study extends these 
findings suggesting that baseline LV dysfunction impacts on survival up to 5 years. However, a 
recently published meta-analysis highlighted the prognostic importance and favourable 
outcomes of heart failure patients with improved ejection fraction under optimal medical therapy, 
compared to those with persistently reduced ejection fraction.26 The role of ejection fraction 
improvement and appropriate identification of patients at higher risk should be evaluated in 
dedicated prospectively designed studies.   
Nevertheless, no specific heart failure treatment has been shown to improve prognosis 
among patients with preserved or mid-range reduced LVEF, and the management is mainly 
directed to the underlying disease entity (i.e. CAD in the present cohort), symptom relief and 
treatment of comorbidities. The lack of benefit of established medical treatment for patients with 
mid-range reduced or preserved LVEF can be partially explained by the heterogeneous 
phenotypes of patients, the absence of dedicated trials to investigate therapeutic strategies, and 
the lack of established surrogate end points for these group of patients.27 At 5 years of follow-up, 
the patients with reduced LVEF remained at increased risk for all-cause mortality, cardiac death 
and the composite of cardiac death, stroke and myocardial infarction compared with both 
preserved and mid-range LVEF group in the present study. Previous studies have evaluated the 
prognostic impact of non-invasive diagnostic tests (e.g. cardiopulmonary exercise testing), 
invasive measurements (e.g. wedge pressure), and biomarkers across the entire spectrum of 
heart failure patients.28-30 However, it remains unclear whether such tools result in modification 
of therapeutic strategies and cost-effective improvement in patient outcomes. 
Consistent with a previous study31, we found that a lower cut-off of LVEF 35% 
discriminates more precisely those patients with more severe systolic dysfunction and impaired 
prognosis, than the guideline proposed cut-off of <40%. However, in our study a small proportion 
of patients (8% of the group of LVEF<40%, corresponding to 0.8% of the whole study cohort 
with LVEF between 35%-40%) would influence the prognostic significance of the 40% cut-off, 
which possibly explains the slightly suboptimal discriminatory ability. Prospective large-scale 
studies should evaluate the clinical relevance of such differences in discriminatory performance. 
 
Limitations 
Several limitations should be acknowledged in the present study. First, this is a non-prespecified 
retrospective analysis of prospectively ascertained clinical data and therefore exploratory in 
nature. However, we analyzed data of a carefully documented series of patients that had been 
fully characterized in terms of baseline characteristics in the framework of RCTs and correlated 
LVEF in the context of different clinical settings with fully adjudicated long-term clinical outcomes 
up to 5-years follow-up. Second, values for LVEF are continuously distributed but measurement 
precision is known to be imperfect and differences up to 10% in individual patients may be 
attributed to measurement errors.32 Third, LVEF was available only at baseline and changes in 
LV function at follow-up were not ascertained; therefore we were unable to consider this 
parameter and its impact on long-term analysis in the present study. Forth, we were unable to 
correlate clinical heart failure status with objective parameters of left ventricular function. Finally, 
in any individual trial, there is always concerns about whether the study populations enrolled 
reflect the patients encountered in clinical practice due to selection criteria, and in toward to this 
aspect this analysis is not different. However, our dataset represents the vast majority of patients 
enrolled in RCTs PCI trials. 
 
Conclusions 
Patients with reduced LVEF<40% or mid-range LVEF 40-49% in the context of CAD undergoing 
clinically indicated PCI are at increased risk of all-cause mortality, cardiac death and the 
composite of cardiac death, stroke and myocardial infarction throughout 5 years of follow-up. 
The recently proposed LVEF cut-offs contribute to the differentiation and risk stratification of 
patients with ischemic heart disease. 
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 FIGURES 
 
FIGURE 1: Flowchart of patients’ selection process and group distribution according to 
LVEF in study population. 
Abbreviations: RCTs, randomized controlled trials; LVEF, left ventricular ejection fraction. 
 
 
FIGURE 2: Time-to-first event curves for patients across the three groups with preserved 
(≥50%), mid-range (40-49%) and reduced (<40%) LVEF. 
Panel A and B: All-cause mortality; Panel C and D: Composite outcome of cardiac death, MI, 
and stroke; Panel E and F: Cardiac death. Estimates are shown as adjusted hazard ratios (HRs) 
with accompanied 95% confidence intervals (CIs). A landmark analysis at time-point of 30 days 
is shown in Panels B, D, and F. 
Abbreviations: MI, myocardial infarction. 
 
 
FIGURE 3: Time-to-first event curves for patients across the three groups with preserved 
(≥50%), mid-range (40-49%) and reduced (<40%) LVEF stratified according to clinical 
presentation. 
Panels A, B, and C: for the primary outcome of all-cause mortality; Panels D, E, and F: for the 
composite endpoint of cardiac death, myocardial infarction, or stroke; Panels G, H, and I: for the 
outcome of cardiac death. Estimates are shown as adjusted hazard ratios (HRs) with 
accompanied 95% confidence intervals (CIs). 
Abbreviations: MI, myocardial infarction; CAD, coronary artery disease; ACS, acute coronary 
syndrome. 
  
FIGURE 4: Fractional polynomial stratified according to clinical setting at baseline for all-
cause mortality. 
Panel A: Overall; Panel B: Stable CAD; Panel C: ACS. 
Abbreviations: HR, hazard ratio; LVEF, left ventricular ejection fraction; CAD, coronary artery 
disease; ACS, acute coronary syndrome. 
 
  
TABLES 
 
TABLE 1: Baseline clinical characteristics. 
Data are shown as n, count (%) and mean±SD as appropriate. 
Abbreviations: LVEF, left ventricular ejection fraction; BMI, body mass index; GFR, glomerular 
filtration rate; CAD, coronary artery disease; MI, myocardial infarction; PCI, percutaneous 
coronary intervention; CABG, coronary artery bypass grafting; NSTE-ACS, non-ST elevation 
acute coronary syndrome; STEMI, ST elevation myocardial infarction.  
 
TABLE 2: Clinical outcomes at 5 years of follow-up across the three groups of preserved 
(≥50%), mid-range (40-49%) and reduced (<40%) LVEF. 
Data shown are adjusted hazard rations (HR) with 95% confidence intervals (CI). Adjustment 
was performed for age, gender, body-mass index, diabetes mellitus, insulin-treatment, diabetes 
diet or oral treatment at baseline, hypertension, current smoker, family history of coronary artery 
disease, previous myocardial infarction, previous percutaneous coronary interventions, previous 
coronary artery bypass-graft, acute coronary syndrome group, renal failure, glycoprotein IIb/IIIa 
antagonist use at procedure. 
Abbreviations: LVEF, left ventricular ejection fraction; HR, hazard ratio; CI, confidence interval; 
MI, myocardial infarction; TLR, target lesion revascularisation; TVR, target vessel 
revascularisation.  
 
TABLE 3: Clinical outcomes at 5 years of follow-up across the three groups of preserved 
(≥50%), mid-range (40-49%) and reduced (<40%) LVEF according to clinical presentation.  
Data shown are adjusted hazard rations (HR) with 95% confidence intervals (CI). Adjustment as 
reported in Table 2. 
Abbreviations: LVEF, left ventricular ejection fraction; HR, hazard ratio; CI, confidence interval; 
CAD, coronary artery disease; ACS, acute coronary syndrome; MI, myocardial infarction; TLR, 
target lesion revascularisation; TVR, target vessel revascularisation.  
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